Stefanie Mandl

Company: Indapta Therapeutics

Job title: Chief Scientific Officer

Seminars:

Leveraging Novel MS Biomarkers to Decode Disease Heterogeneity & Treatment Response for Precision Therapeutic Development 9:15 am

Identifying novel MS biomarkers to predict individual risk, enabling personalized prevention strategies Validating progression-linked biomarkers that track disease severity, to optimize treatment timing and selection Linking biomarkers to therapeutic response for emerging drugs to accelerate clinical trial success and approvalRead more

day: Conference Day Two